Inhibitors targeting the SUMOylation pathway: A patent review 2012‑2015 (Review)
- Authors:
- Yanjun Zhou
- Chunmei Ji
- Mengda Cao
- Miao Guo
- Wen Huang
- Weiwei Ni
- Ling Meng
- Haiwei Yang
- Ji‑Fu Wei
-
Affiliations: Research Division of Clinical Pharmacology, Jiangsu Province People's Hospital, Nanjing, Jiangsu 210029, P.R. China, Department of Urology, Jiangsu Province People's Hospital, Nanjing, Jiangsu 210029, P.R. China - Published online on: November 1, 2017 https://doi.org/10.3892/ijmm.2017.3231
- Pages: 3-12
This article is mentioned in:
Abstract
Herrmann J, Lerman LO and Lerman A: Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res. 100:1276–1291. 2007. View Article : Google Scholar : PubMed/NCBI | |
Flotho A and Melchior F: Sumoylation: A regulatory protein modification in health and disease. Annu Rev Biochem. 82:357–385. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bohren KM, Nadkarni V, Song JH, Gabbay KH and Owerbach D: A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem. 279:27233–27238. 2004. View Article : Google Scholar : PubMed/NCBI | |
Geiss-Friedlander R and Melchior F: Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol. 8:947–956. 2007. View Article : Google Scholar : PubMed/NCBI | |
Tatham MH, Jaffray E, Vaughan OA, Desterro JM, botting CH, Naismith JH and Hay RT: Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem. 276:35368–35374. 2001. View Article : Google Scholar : PubMed/NCBI | |
Yang W and Paschen W: SUMO proteomics to decipher the SUMO-modified proteome regulated by various diseases. Proteomics. 15:1181–1191. 2015. View Article : Google Scholar : | |
Hannich JT, Lewis A, Kroetz MB, Li SJ, Heide H, Emili A and Hochstrasser M: Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J Biol Chem. 280:4102–4110. 2005. View Article : Google Scholar | |
Hecker CM, Rabiller M, Haglund K, Bayer P and Dikic I: Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem. 281:16117–16127. 2006. View Article : Google Scholar : PubMed/NCBI | |
Song J, Durrin LK, Wilkinson TA, Krontiris TG and Chen Y: Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci USA. 101:14373–14378. 2004. View Article : Google Scholar : PubMed/NCBI | |
Kumar A and Zhang KY: Advances in the development of SUMO specific protease (SENP) inhibitors. Comput Struct Biotechnol J. 13:204–211. 2015. View Article : Google Scholar : PubMed/NCBI | |
Hickey CM, Wilson NR and Hochstrasser M: Function and regulation of SUMO proteases. Nat Rev Mol Cell Biol. 13:755–766. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bettermann K, Benesch M, Weis S and Haybaeck J: SUMOylation in carcinogenesis. Cancer Lett. 316:113–125. 2012. View Article : Google Scholar | |
Olsen SK, Capili AD, Lu X, Tan DS and Lima CD: Active site remodelling accompanies thioester bond formation in the SUMO E1. Nature. 463:906–912. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kumar A, Ito A, Hirohama M, Yoshida M and Zhang KY: Identification of sumoylation inhibitors targeting a predicted pocket in Ubc9. J Chem Inf Model. 54:2784–2793. 2014. View Article : Google Scholar : PubMed/NCBI | |
Kumar A, Ito A, Hirohama M, Yoshida M and Zhang KY: Identification of sumoylation activating enzyme 1 inhibitors by structure-based virtual screening. J Chem Inf Model. 53:809–820. 2013. View Article : Google Scholar : PubMed/NCBI | |
Mattoscio D and Chiocca S: SUMO pathway components as possible cancer biomarkers. Future Oncol. 11:1599–1610. 2015. View Article : Google Scholar : PubMed/NCBI | |
Schulz S, Chachami G, Kozaczkiewicz L, Winter U, Stankovic-Valentin N, Haas P, Hofmann K, Urlaub H, Ovaa H, Wittbrodt J, et al: Ubiquitin-specific protease-like 1 (USPL1) is a SUMO isopeptidase with essential, non-catalytic functions. EMbO Rep. 13:930–938. 2012. View Article : Google Scholar : PubMed/NCBI | |
Shin EJ, Shin HM, Nam E, Kim WS, Kim JH, Oh BH and Yun Y: DeSUMOylating isopeptidase: A second class of SUMO protease. EMBO Rep. 13:339–346. 2012. View Article : Google Scholar : PubMed/NCBI | |
Shirong L and Wei H: Sumoylation - a muitffunctional post-translational protein modification. J Med Mol Biol. 3:212–215. 2006. | |
Liu X, Xu Y, Pang Z, Guo F, Qin Q, Yin T, Sang Y, Feng C, Li X, Jiang L, et al: Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer. J Hematol Oncol. 8:672015. View Article : Google Scholar : PubMed/NCBI | |
Chen SF, Gong C, Luo M, Yao HR, Zeng YJ and Su FX: Ubc9 expression predicts chemoresistance in breast cancer. Chin J Cancer. 30:638–644. 2011. View Article : Google Scholar : PubMed/NCBI | |
Rabellino A, Carter B, Konstantinidou G, Wu SY, Rimessi A, byers LA, Heymach JV, Girard L, Chiang CM, Teruya-Feldstein J, et al: The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res. 72:2275–2284. 2012. View Article : Google Scholar : PubMed/NCBI | |
Li T, Huang S, Dong M, Gui Y and Wu D: Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy. Urol Oncol. 31:1539–1545. 2013. View Article : Google Scholar | |
Bossis G, Sarry JE, Kifagi C, Ristic M, Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, et al: The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs. Cell Rep. 7:1815–1823. 2014. View Article : Google Scholar : PubMed/NCBI | |
Dassouki Z, Sahin U, El Hajj H, Jollivet F, Kfoury Y, Lallemand-Breitenbach V, Hermine O, de Thé H and Bazarbachi A: ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation. Blood. 125:474–482. 2015. View Article : Google Scholar | |
Chen Y, Horne D, Li YJ, Ma LY, Perkins-Harki AL and Su Y: Multi-valent poly-ubl chain inhibitors and methods of use. US Patent 0302815. Filed February 21, 2012; issued August 5, 2014. | |
Zhao B, Villhauer EB, Bhuripanyo K, Kiyokawa H, Schindelin H and Yin J: SUMO-mimicking peptides inhibiting protein SUMOylation. Chembiochem. 15:2662–2666. 2014. View Article : Google Scholar : PubMed/NCBI | |
Butterworth KT, Coulter JA, Jain S, Forker J, McMahon SJ, Schettino G, Prise KM, Currell FJ and Hirst DG: Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles: Potential application for cancer therapy. Nanotechnology. 21:2951012010. View Article : Google Scholar : PubMed/NCBI | |
Li YJ, Perkins AL, Su Y, Ma Y, Colson L, Horne DA and Chen Y: Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation. Proc Natl Acad Sci USA. 109:4092–4097. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chithrani DB, Jelveh S, Jalali F, van Prooijen M, Allen C, Bristow RG, Hill RP and Jaffray DA: Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res. 173:719–728. 2010. View Article : Google Scholar : PubMed/NCBI | |
Langston SP, Olhava EJ and Vyskocil S: Inhibitors of E1 activating enzymes. EP Patent 2402334 A1. Filed February 2, 2006; issued Junuary 26, 2012. | |
Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI | |
Diffey MO, England Db, Hu ZG, Ito M, Langston SP, Mcintyre C, Mizutani H and Xu H: Heteroaryl compounds useful as inhibitors of SUMO activating enzyme. WO Patent 2015002994 A2. Filed July 1, 2014; issued January 8, 2015. | |
Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JD Jr, et al: The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 115:2827–2834. 2010. View Article : Google Scholar : | |
Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, et al: A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 335:348–353. 2012. View Article : Google Scholar | |
Chen Y, Li YJ, Divlianska D, Bobkova E and Roth G: Singleton inhibitors of SUMOylation enzymes and methods for their use. US Patent 20130317101 A1. Filed May 9, 2013; issued November 28, 2013. | |
Chen Y and Li YJ: Singleton inhibitors of SUMOylation enzymes and methods for their use. WO Patent 064898 A1. Filed May 9, 2013; issued January 19, 2016. | |
Maas M, Nelemans PJ, Valentini V, Crane CH, Capirci C, Rödel C, Nash GM, Kuo LJ, Glynne-Jones R, García-Aguilar J, et al: Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. Int J Cancer. 137:212–220. 2015. View Article : Google Scholar | |
García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD and Rothenberger DA: A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 46:298–304. 2003. View Article : Google Scholar : PubMed/NCBI | |
Chen Y and Li YJ: Bicyclic and tricyclic inhibitors of SUMOylation enzymes and methods for their use. WO Patent 064897 A2. Filed November 9, 2011; issued May 18, 2012. | |
Chen Y, Li YJ, Divlianska D, Bobkova E, Roth G, Jun PU and Khan P: Bicyclic and tricyclic inhibitors of SUMOylation enzymes and methods for their use. US Patent 20130245032 A1. Filed May 9, 2013; issued September 19, 2013. | |
Chen Y, Li YJ, Divlianska D, bobkova E, Roth G, Jun PU and Khan P: Inhibitors of small ubiquitin-like modifier enzymes with substituted pyrrolo(2,3-B)quinoxalines. US Patent 9045483 B2. Filed May 9, 2013; issued June 2, 2015. | |
Lalonde JP, Lim R, Scaife R, Gallagher S and Klinken SP: HLS-5 a control SUMOylation agent. EP Patent 2545935 A1. Filed October 6, 2006; issued January 16, 2013. | |
Klinken SP, Lalonde JP, Lim R, Scaife R and Gallagher S: SUMOylation control agent and uses thereof. US Patent 20130330738 A1. Filed Junuary 4, 2013; issued December 12, 2013. | |
Knuutila S, Aalto Y, Autio K, Björkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, et al: DNA copy number losses in human neoplasms. Am J Pathol. 155:683–694. 1999. View Article : Google Scholar : PubMed/NCBI | |
Lalonde JP, Lim R, Ingley E, Tilbrook PA, Thompson MJ, McCulloch R, Beaumont JG, Wicking C, Eyre HJ, Sutherland GR, et al: HLS5, a novel RBCC (ring finger, B box, coiled-coil) family member isolated from a hemopoietic lineage switch, is a candidate tumor suppressor. J Biol Chem. 279:8181–8189. 2004. View Article : Google Scholar | |
Kimura F, Suzu S, Nakamura Y, Nakata Y, Yamada M, Kuwada N, Matsumura T, Yamashita T, Ikeda T, Sato K, et al: Cloning and characterization of a novel RING-B-box-coiled-coil protein with apoptotic function. J Biol Chem. 278:25046–25054. 2003. View Article : Google Scholar : PubMed/NCBI | |
Alshareeda AT, Negm OH, Green AR, Nolan C, Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO and Rakha EA: SUMOylation proteins in breast cancer. Breast Cancer Res Treat. 144:519–530. 2014. View Article : Google Scholar : PubMed/NCBI | |
Coppola D, Parikh V, boulware D and Blanck G: Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol. 135:1287–1291. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chen P, Zhao D, Sun Y, Huang L, Zhang S and Yuan Y: Protein inhibitor of activated STAT-1 is downregulated in gastric cancer tissue and involved in cell metastasis. Oncol Rep. 28:2149–2155. 2012. View Article : Google Scholar : PubMed/NCBI | |
Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ, Qian X, Chen H, Gimenez-Capitan A, Meng F, et al: mRNA expression of bRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst. 103:1552–1556. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hoefer J, Schäfer G, Klocker H, Erb HH, Mills IG, Hengst L, Puhr M and Culig Z: PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol. 180:2097–2107. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Li S, Li S, Li YJ, Su Y, Wong S and Zaia J: Inhibitors of deSUMOylation enzymes and methods for their use. WO Patent 2012064887 A1. Filed November 9, 2011; issued May 18, 2012. | |
Chen Y: Methods of identifying SENP1 inhibitors. US Patent 20140302525 A1. Filed April 7, 2014; issued October 9, 2014. | |
Madu IG, Namanja AT, Su Y, Wong S, Li YJ and Chen Y: Identification and characterization of a new chemotype of noncovalent SENP inhibitors. ACS Chem Biol. 8:1435–1441. 2013. View Article : Google Scholar : PubMed/NCBI | |
Chen CH, Namanja AT and Chen Y: Conformational flexibility and changes underlying activation of the SUMO-specific protease SENP1 by remote substrate binding. Nat Commun. 5:49682014. View Article : Google Scholar : PubMed/NCBI | |
Madu IG, Li S, Li B, Li H, Chang T, Li YJ, Vega R, Rossi J, Yee JK, Zaia J, et al: A Novel Class of HIV-1 Antiviral Agents Targeting HIV via a SUMOylation-Dependent Mechanism. Sci Rep. 5:178082015. View Article : Google Scholar : PubMed/NCBI | |
Wang LS, Sun HY, Wu ZZ, Xiao FJ, Wang H and Yang YF: SENP1 protein inhibitors and uses thereof. CN Patent 104436196 A. Filed September 23, 2013; issued March 25, 2015. | |
Zhang J, Cheng JK, Lu SY, Cheng YY, Zhang JM and Huang M: Senp1 small molecule inhibitors and their applications. CN Patent 103961348 B. Filed February 5, 2013; issued August 17, 2016. | |
Chen Y, Wen D, Huang Z, Huang M, Luo Y, Liu B, Lu H, Wu Y, Peng Y and Zhang J: 2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a novel class of SENP1 inhibitors: Virtual screening, synthesis and biological evaluation. Bioorg Med Chem Lett. 22:6867–6870. 2012. View Article : Google Scholar : PubMed/NCBI | |
Cheng J, Kang X, Zhang S and Yeh ET: SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell. 131:584–595. 2007. View Article : Google Scholar : PubMed/NCBI | |
Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM and Yeh ET: SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem. 285:25859–25866. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yamaguchi T, Sharma P, Athanasiou M, Kumar A, Yamada S and Kuehn MR: Mutation of SENP1/SuPr-2 reveals an essential role for desumoylation in mouse development. Mol Cell Biol. 25:5171–5182. 2005. View Article : Google Scholar : PubMed/NCBI | |
Cheng J, Bawa T, Lee P, Gong L and Yeh ET: Role of desumoylation in the development of prostate cancer. Neoplasia. 8:667–676. 2006. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Cheng JK, Huang M, Chen YY, Huang ZM, Lu SY and Shi T: SENP2 small molecule inhibitor and applications thereof. CN Patent 103877078 A. Filed December 20, 2012; issued June 25, 2014. | |
Dou QP and Zonder JA: Overview of proteasome inhibitor-based anticancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets. 14:517–536. 2014. View Article : Google Scholar | |
Chen JW, Ink BS and Lewis AP: Cysteine protease polypeptides GB2371801. 2002 | |
Ink BS and Lewis AP: Cysteine protease polypeptide GB2372504. 2002 | |
Chen JW, Ink BS and Lewis AP: Cysteine protease polypeptide GB2372994. 2002 | |
Góra J and Latajka R: Involvement of cysteine proteases in cancer. Curr Med Chem. 22:944–957. 2015. View Article : Google Scholar | |
Wu HJ, Liu WD, Hong YD and Guo QP: Identification of a breast cancer suppressor and methods for use CN101923095. 2010 | |
German RA and Sangita P: Modulation of cellular protein function by artifical SUMO ligases. US Patent 20120246757 A1. Filed March 22, 2012; issued September 27, 2012. |